Cortellis Competitive Intelligence

First-in-class Tazverik launched for rare sarcoma, wider use will drive market value

Epizyme’s first-in-class EZH2 (enhancer of zeste homolog 2) inhibitor Tazverik (tazemetostat) has become the first therapy to be made available in the U.S. for the treatment of epithelioid sarcoma (ES), a rare soft tissue tumor with a significant unmet need.1,2,3 The drug was granted accelerated approval in January 2020 for the treatment of patients aged […]

Cystic fibrosis: Market shake-up to come?

This article, a Cortellis Market Insight report, is adapted from the author’s comprehensive Cystic Fibrosis Disease Report. Publication of the report coincides with Cystic Fibrosis Awareness Month in May in the U.S. and Canada, which aims to raise awareness and improve understanding of the disease. Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies have transformed […]

Busy biopharma M&A activity closed out 2018

During the fourth quarter of 2018, Cortellis Deals Intelligence registered 140 new mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in […]

Biopharma licensing finished with a strong Q4

During the fourth quarter of 2018, Cortellis Competitive Intelligence   registered 1,073 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $46.1 billion as part of its ongoing coverage of licensing activity in the life sciences sector. The totals represented a 7.4% increase from 994 and a 41.4% increase from $27 billion […]

In multiple myeloma, B-cell maturation antigen emerges as promising target

This is a Cortellis Market Insight report, an ongoing series featuring expert reviews of hot topics in the biopharma field, with analysis and discussion on the factors currently affecting the industry. Data leveraged for this analysis were gathered from Cortellis from Clarivate Analytics. There remains an unmet need for patients with multiple myeloma (MM), particularly […]

Biopharma M&A engine fires up as new year rings in big deals

Bristol-Myers Squibb (BMS) Co.’s $74 billion bid for Celgene Corp. – which, if it closes, will become the largest M&A in biopharma history – “made for a fascinating opening” to the J.P. Morgan Healthcare Conference (JPM), said Jamie Munro, global practice leader, portfolio and licensing at Clarivate Analytics, especially given Celgene’s historic placemark as the […]

Neuroscience lures dealmakers despite drug development challenges

While no other therapeutic area matches oncology in dealmaking volume, neurology is “among the nearest contenders.” That’s the main theme of recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Trends in Neuroscience Dealmaking,” was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, […]

Licensing deals driving the life sciences industry in Q3: notes and trends

During the third quarter of 2018, Cortellis Competitive Intelligence registered 984 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $26 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 1,060 and $20.8 billion in the second quarter and 1,158 and $33.6 billion […]

Q3 M&A deals driving the life sciences industry

Trends in M&A volume and deal value During the third quarter of 2018, Cortellis Deals Intelligence registered 131 new mergers and acquisitions (M&A) with a total disclosed deal value of $16 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 113 and $104.6 billion in the second […]

Orphan drug access varies across multiple markets

European countries differ in their value assessment of new orphan drugs, but steps can be taken to create a more harmonized, comparable and rational evidence-based decision-making system in Europe, two experts from the London School of Economics Health reported at the Ninth Orphan Drug Congress 2018. The presentation by Aris Angelis and Panos Kanavos covered […]